04 September 2010
Keywords: influenza treatment, Biota Holdings, CS-8958
Article | 10 August 2009
Australia’s Biota Holdings has announced successful results from the Asian Phase III clinical trials of CS-8958, its second generation influenza treatment. CS-8958 now has been assigned the new name of laninamivir’by the World Health Organization under its International Non-proprietary Names (INN) drug identification system. Laninamivir is a long-acting neuraminidase inhibitor (LANI) and is co-owned with Japan’s Daiichi Sankyo.
In the Phase III trial in adults, a single inhaled dose of laninamivir was shown to be as effective as oseltamivir (Tamiflu) administered orally twice daily for five days (total of 10 doses). Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.